Key Companies Covered in the Global Mesenchymal Stem Cell (MSC) Market Research Report by Kenneth Research Are Cell Applications, Inc., Celprogen Inc., STEMCELL Technologies Inc., Axol Bioscience Ltd., Cytori Therapeutics Inc., Proteona Pte. Ltd., BrainStorm Cell Limited, Stemedica Cell Technologies, Inc., Mesoblast Ltd., ScienCell Research Laboratories, Inc., Neuromics, and other key market players.
New York, Aug. 04, 2022 (GLOBE NEWSWIRE) -- According to the World Health Organization, the number and percentage of the geriatric population, i.e., adults 60 years of age and older, is increasing. In 2019, 1 billion people were 60 years of age or older across the globe. This number is anticipated to increase to 1.4 billion by 2030 and to 2.1 billion by 2050. In addition to this, it was also observed that 85% of older persons have at least one chronic health issue, and 60% have two or more.
Kenneth Research has published a detailed market report on ‘Global Mesenchymal Stem Cell (MSC) Market’ which includes the ongoing industry innovations and recent trends being adopted by the major industry players to achieve their business targets. Apart from that, the inclusive data on market size, growth rate, market revenue share, growth opportunities and challenges for the market players along with worldwide analysis on five major regions – North America, Latin America, Europe, Asia Pacific and Middle East & Africa has been provided in the report.
According to the National Library of Medicine, globally, a significant 310 million major surgeries were performed each year as of 2020. Amongst them, around 40 to 50 million were done in USA and 20 million in Europe. The global mesenchymal stem cell (MSC) market generated revenue of around USD 3 billion in the year of 2021. The market is estimated to grow at a CAGR of ~14% over the forecast period, i.e., 2022-2031. The growth of the market can majorly be attributed to the increasing aging population who are prone to different types of diseases, growing awareness regarding the treatment of injuries and surgery procedures, and the rising usage of mesenchymal stem cells as a substitute surgery for knee replacement and other operative procedures. Moreover, the increasing cost of these procedures and surgeries is estimated to elevate the overall health expenditure across the globe and which in turn is estimated to be a prime factor to drive market growth during the forecast period. According to the data by The World Bank, in 2019, the global health expenditure accounted to 9.831% of the GDP.
Get a Sample PDF of This Report @ https://www.kennethresearch.com/sample-request-10082369
Furthermore, increasing road accidents and deaths due to accidents around the world is another factor to drive the market growth over the forecast period. Most of the road accidents lead to severe or traumatic injuries which require surgeries for treatment. It was noticed that approximately 1.3 million people die each year because of road traffic crashes. Additionally, rising disposable income per capita among people across the globe is resulting into better treatment for injuries and rising demand for adult stem cells such as, mesenchymal stem cells. It was noticed that, globally the disposable income per capita in 2020 was USD 8784. Hence, this is anticipated to be a significant factor to propel the growth of the global mesenchymal stem cell (MSC) market during the forecast period.
Regionally, the global mesenchymal stem cell (MSC) market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa. The North America region witnessed noteworthy growth in the global market for mesenchymal stem cell (MSC) in the year 2021. This growth can be accredited to the large number of aging population, and increasing incidence of cancers in the region. For instance, in the United States, 1,752,735 new cases of cancer were reported in 2019, while 599,589 people passed away from the disease. Additionally, the increasing research and development activities, rising healthcare expenditure, and presence of key market players in the region are estimated to drive the market growth over the forecast period.
Browse to access In-depth research report on the Global Mesenchymal Stem Cell (MSC) Market with detailed charts and figures: https://www.kennethresearch.com/report-details/mesenchymal-stem-cells-market/10082369
On the other hand, the global mesenchymal stem cell (MSC) market in the Asia Pacific region is expected to grow with the highest CAGR during the forecast period on the back of increasing number of aging patients, government’s initiative such as check-up camps, patient friendly medical policies, and sufficient funding to healthcare sector. According to the Asian Development Bank, the number of elderly persons in the Asia Pacific region will reach 1.3 billion by 2050. For a clearer understanding, one in four persons will be older than 60. Among the Asia Pacific countries, China and India are expected to be the fastest growing MSC markets in the region owing to the rising geriatric population and increasing research and development initiatives in these regions.
The study further incorporates Y-O-Y growth, demand & supply and forecast future opportunity in North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC [Finland, Sweden, Norway, Denmark], Poland, Turkey, Russia, Rest of Europe), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Asia-Pacific (China, India, Japan, South Korea, Indonesia, Singapore, Malaysia, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa).
Get a Sample PDF of the Global Mesenchymal Stem Cell (MSC) Market @ https://www.kennethresearch.com/sample-request-10082369
The global mesenchymal stem cell (MSC) market is segmented on the basis of application into disease modelling, oncology disorders, drug development & discovery, stem cell banking, tissue engineering, and others. Out of these, the oncology disorder segment is anticipated to hold the largest share in the market by the end of 2031 and is expected to grow at the highest CAGR during the forecast period. The growth of this segment can be majorly accredited to increasing cancer cases, wherein the branch of oncology deals with the prevention, treatment, and diagnosis of cancer. Additionally, upsurge in the number of cancer patients and cancer caused deaths worldwide is expected to be a major factor to fuel the growth of this segment over the forecast period. According to the World Health Organization, nearly 10 million people died of cancer across the globe in 2020.
Furthermore, the global mesenchymal stem cell (MSC) market is segmented based on stem cells indication into cardiovascular disease, liver disease, cancer, and others. Out of these, the cancer segment is anticipated to hold a substantial market share over the forecast period on the back of the increasing prevalence of cancer around the globe, and rising deaths caused by various types of cancer. It was noted that, in 2020, lung cancer caused 1.80 million deaths, colon and rectum cancer caused 916 000 deaths, liver cancer caused 830 000 deaths, and breast cancer caused 685 000 deaths across the globe.
The global mesenchymal stem cell (MSC) market is also segmented on the basis of treatment type, product & service, and source of isolation
Global Mesenchymal Stem Cell (MSC) Market, Segmented by Treatment Type
Global Mesenchymal Stem Cell (MSC) Market, Segmented by Product & Service
Global Mesenchymal Stem Cell (MSC) Market, Segmented by Source of Isolation
Enquiry before Buying This Report @ https://www.kennethresearch.com/sample-request-10082369
Some of the prominent players and their company profiling mentioned in the report include Cell Applications, Inc., Celprogen Inc., STEMCELL Technologies Inc., Axol Bioscience Ltd., Cytori Therapeutics Inc., Proteona Pte. Ltd., BrainStorm Cell Limited, Stemedica Cell Technologies, Inc., Mesoblast Ltd., ScienCell Research Laboratories, Inc., Neuromics, Inc., and others. The profiling enfolds growth opportunities, challenges, market trends, competitive analysis and positioning, along with the strategies used by them to stay ahead of their competitors.
Thyroid Disorder Market Analysis by Disorder Type (Hypothyroidism, and Hyperthyroidism); by Treatment Type (Medications, Radioactive Iodine Therapy, and Surgery); by Route of Administration (Oral, and Intravenous); and by End-User (Hospitals, and Clinics)-Global Supply & Demand Analysis & Opportunity Outlook 2022-2031
Clinical Laboratory Services Market Analysis by Service Provider (Clinic-Based, Hospital-Based, and Independent Laboratories); and by Test Type (Hematology, Human & Tumor Genetics, Cytology, Immunology, and Others)-Global Supply & Demand Analysis & Opportunity Outlook 2022-2031
Disposable Syringes Market Segmentation by Type (General/Conventional, Safety, and Pre-Filled Syringes); by Syringe Tip (Luer-Lock, Slip, Eccentric, and Catheter Syringe Tips); by Application (Immunization, and Therapeutic Injections, and Others); by End-User (Hospitals, Diagnostic Laboratories, Blood Banks, Pharmaceutical Companies, and Others)-Global Demand Analysis & Opportunity Outlook 2021-2031
Medical Nutrition Market Analysis by Product Type (Enteral, Oral Supplements, and Parenteral Nutrition); by End Users (Pediatric, and Adult Nutrition); and by Distribution Channels (Hospitals, Retail Pharmacies, and E-commerce Websites)-Global Supply & Demand Analysis & Opportunity Outlook 2022-2031
Laparoscopy Devices Market Analysis by Application (Gynecological, Urological, General, Bariatric, and Other Surgery); by End Users (Ambulatory, Hospital, and Clinic); and by Product (Robotic Assisted Systems, Laparoscopes, Hand Access Instruments, Energy Systems, and Others)-Global Supply & Demand Analysis & Opportunity Outlook 2022-2031
Kenneth Research is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment, etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision so as to avoid future uncertainties.
Web: https://www.kennethresearch.com/
UNITY Biotechnology Inc (NASDAQ: UBX) shares are skyrocketing after 12- and 18-week data from its Phase 2 BEHOLD study of UBX1325 for diabetic macular edema (DME). DME is a diabetic complication that affects the blood vessels in the back of your eye. At 18 weeks after a single UBX1325 injection, the mean change in BCVA of UBX1325-treated subjects was an increase of 6.1 ETDRS letters, representing an improvement of +5.0 ETDRS letters compared to sham-treated subjects. Related: UNITY Biotech Stock
New drugs from Eli Lilly and Novo Nordisk have shown striking results in studies. If insurers step up to back them, the drugs—and the stocks—could take off.
Vaxxinity missed out on Operation Warp Speed and the first round of COVID-19 vaccines, but CEO Mei Mei Hu is focused on the second generation and ongoing global needs.
The U.S. Centers For Disease Control and Prevention has relaxed some guidelines around COVID-19, including the quarantine recommendation for people who have been exposed. Officials say the new guidelines are meant to educate people on how to stay safe without causing much disruption to life, school and work.
The study, which was recently published in the journal “Scientific Reports,” found that gait patterns among Japanese children aged 6 to 12 vary from those in other developed countries. Age related variations in lower limb movements while walking were studied by scientists from Nagoya University in Japan. For Japanese children in the 11-12 year age group, the number of steps performed each minute was higher than those in the 6-8 year age group.
Pfizer (PFE) offers to buy Global Blood Therapeutics (GBT) for $5.4 billion in cash. J&J (JNJ) to discontinue selling talc-based baby powder globally from 2023.
Aptinyx (APTX) reports disappointing data from a mid-stage study assessing NYX-2925 for the treatment of fibromyalgia. Stocks decline
(TSX: CWEB) (OTC: CWBHF) Charlotte's Web Holdings, Inc. ("Charlotte's Web," "CW" or the "Company"), the market leader in full-spectrum hemp extract CBD products, today announced plans to unveil a product line catering to the sports vertical. The products are currently undergoing the NSF for Sport® certification process with NSF, a third-party organization that manufacturers, regulators, and consumers look to for the development of public health standards and certification marks that help protect
Big pharma stocks, such as Glaxo (GSK), Sanofi (SNY), Pfizer (PFE) and Consumer stock Haleon (HLN), decline due to the litigation surrounding the heartburn drug Zantac (ranitidine).
Friends up north and across Tampa Bay snickered when Brian Lafferty revealed where he’d bought a new home. His 30-year-old daughter in Boston called to express concern. Even his ex-wife asked him about it. “Without exception, every person I’ve told I bought a house in The Villages has asked the same thing,” Lafferty said. “‘Isn’t that the STD capital of the United States?’” The Villages, a ...
The FTSE 100 pharmaceutical giant's share price suffered its biggest drop since 1998 on Thursday.
Vedanta, a microbiome startup that raised $68 million just over a year ago is letting about 20% of its staff go.
When it comes to liver health, many people focus on one thing that's known to cause problems: excessive alcohol. But experts say you're probably consuming something else that could be putting this vital organ in distress. Eating too much of this one popular food may cause non-alcoholic fatty liver disease (NAFLD), which can easily lead to serious complications. As NAFLD progresses, it can lead to inflammation and compromised function, which in turn can cause scarring (cirrhosis), swelling, liver
What are the symptoms of skin cancer? Colorado meteorologist Kathy Sabine was diagnosed with basal cell carcinoma, squamous cell carcinoma, shared scar photos.
Concentrating for long periods fills our brains with fatigue-inducing toxins – so what can we do about it? By Imy Brighty-Potts.
LONDON (Reuters) -Shares in GSK, Sanofi and Haleon fell sharply on Thursday, following declines earlier this week, amid growing investor concerns about U.S. litigation focused on a heartburn drug that contained a probable carcinogen. GSK shares fell more than 10%, Sanofi's stock sagged about 3.3% and Haleon's shares slipped nearly 5% at the close of trading on Thursday. GSK, the U.S. Food & Drug Administration (FDA) and the European Medicines Agency (EMA) have all concluded after experiments that there is no evidence of a causal association between therapy with the heartburn drug ranitidine and the development of cancer in patients, GSK said in a statement in response to the litigation.
After a UBS analyst's note sparked a two-day plunge in the drug makers, their shares rallied Friday after they said there is no evidence the heartburn drug causes cancer.
The new guidelines from the Atlanta-based CDC loosen recommendations for people with direct exposure to the virus. It no longer recommends immediate quarantine.
The latest guidance aligns with the recommendations set for those who are up to date on their COVID-19 vaccines
Palm Springs resident Kyle Wilkins received a Jynneos vaccine then noticed sores and other typical monkeypox symptoms two days later.